Takeda Pharmaceutical's United Kingdom subsidiary has begun working with C4X Discovery to improve its lead discovery and hit identification. The agreement is centered on C4XD's 3D drug technology, a nuclear magnetic resonance-based method of viewing the structure of a molecule.
This week a German team presented data from a database analysis study that found a link between a diabetes drug and a slight dip in the risk of developing Alzheimer's.
In the midst of an unprecedented dealmaking spree that has produced $139 billion in pharmaceutical mergers this quarter alone, one country has been conspicuously absent: Japan. Even such giants as Astellas Pharma and Takeda Pharmaceutical, which have led M&A runs in Japan in the past, have stayed on the sidelines. Why?
Japan's Takeda Pharmaceutical nabbed European approval for its treatment for ulcerative colitis and Crohn's disease, Entyvio, after winning the FDA's blessing last week
Wipro has won a $400 million contract to manage Takeda's infrastructure. Takeda inked the deal to consolidate its operations, with Wipro becoming its primary provider of IT infrastructure management services.
In federal court in Las Vegas, a trial over the cancer risks of Takeda's Actos drug wrapped up Tuesday, leaving the jury to decide whether the diabetes remedy triggered the plaintiffs' disease--and if so, how much they should collect from the Japanese drugmaker.
A Louisiana jury pummeled Takeda Pharmaceutical and Eli Lilly & Co. with $9 billion in punitive damages in a liability suit over their blockbuster diabetes drug Actos. It's one for the record books, an amount so far beyond normal that even the victorious lawyers discounted it.
Japan's health ministry is one of the world's toughest when it comes to demanding truth in advertising. Violators can be thrown in prison. And the newest target of its scrutiny is Takeda Pharmaceutical, which is now admitting it may have mismarketed its hypertension drug Blopress.
Japan's health ministry is one of the world's toughest when it comes to demanding truth in advertising. The newest target of its scrutiny is Takeda Pharmaceutical, which is now admitting it may have mis-marketed its hypertension drug Blopress. Takeda's CEO, Yasuchika Hasegawa, told reporters at a news conference on Monday that the company used "inappropriate expressions" to advertise the drug, according to The Wall Street Journal.
A new public health partnership called the Global Health Innovative Technology Fund is doling out $5.7 million in grants to 6 programs across the globe to boost research and development of promising vaccines against malaria, tuberculosis and Chagas disease.